Physician profile
Pascal P Bordy
NPI 1952514283
$3,599.69
in general payments reported to CMS, 2019-2025
21 companies · $577 in 2025
The $577 reported for 2025 was more than what 76% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $228 · 2020: $483 · 2021: $571 · 2022: $716 · 2023: $514 · 2024: $510 · 2025: $577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,602.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,601.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $950.95 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $629.06 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $383.51 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $255.64 | 2019-2022 | |
| Amgen INC. | $201.44 | 2022-2025 | Repatha, Otezla, Otezla |
| Dexcom, INC. | $183.59 | 2021-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $166.73 | 2020-2022 | |
| Glaxosmithkline, LLC. | $142.02 | 2021-2024 | Trelegy Ellipta |
| Otsuka America Pharmaceutical, INC. | $124.99 | 2023 | Rexulti |
| Coloplast Corp | $80.58 | 2022 | |
| Amarin Pharma, INC. | $79.54 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $74.30 | 2019-2020 | |
| Exact Sciences Corporation | $72.15 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $67.06 | 2021-2022 | |
| Abbvie INC. | $44.73 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $37.49 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.96 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $25.27 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $21.37 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $17.77 | 2023 | Seglentis |
| Nestle Healthcare Nutrition INC. | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pascal Bordy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.